Differentiated thyroid carcinoma
Conditions
Interventions
Low-dose 131I treatment group:After surgery for differentiated thyroid carcinoma, oral administration of 30 mCi of 131I is performed for thyroid remnant ablation.
High-dose 131I treatment group:After surgery for differentiated thyroid carcinoma, oral administration of 100 mCi of 131I is performed for thyroid remnant ablation.
Sponsors
Affiliated Hospital of North Sichuan Medical College
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Pathologically confirmed as DTC (papillary carcinoma, follicular carcinoma, oncocytic carcinoma) 2. Postoperatively classified as low-to-intermediate risk or intermediate-to-high risk according to the ATA 2025 criteria 3. Scheduled to receive iodine-131 remnant ablation therapy 4. Voluntarily signed the informed consent form
Exclusion criteria
Exclusion criteria: 1. Undifferentiated carcinoma, medullary carcinoma and other non-DTC types 2. Complicated with other malignant tumors or severe underlying diseases (such as renal insufficiency, heart failure) 3. Metastasis occurred outside the lymph nodes 4. Pregnant or lactating women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Success rate of remnant ablation after iodine-131 therapy for differentiated thyroid cancer; | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of adverse reactions related to iodine-131 therapy; | — |
Countries
China
Contacts
Public ContactCao Lingzhi
Department of Nuclear Medicine, Affiliated Hospital of North Sichuan Medical College
Outcome results
None listed